Exelixis v. Cipla: Cabozantinib Patent Dispute Dismissed in 61 Days
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Exelixis, Inc. v. Cipla Limited |
| Case Number | 1:24-cv-00565 (D. Del.) |
| Court | Delaware District Court |
| Duration | May 2024 – July 2024 61 Days |
| Outcome | Dismissed Without Prejudice |
| Patents at Issue | |
| Accused Products | 60 mg Cabozantinib (S)-Malate Tablets (Generic CABOMETYX®) |
Case Overview
The Parties
⚖️ Plaintiff
California-based oncology biopharmaceutical company whose commercial flagship, CABOMETYX® (cabozantinib), is FDA-approved for various cancers.
🛡️ Defendant
Leading global generic pharmaceutical manufacturer headquartered in Mumbai, India, with its U.S. subsidiary, CIPLA USA, Inc., as co-defendant.
Patents at Issue
This high-stakes case involved five U.S. patents protecting cabozantinib (S)-malate — the active compound in blockbuster oncology drug CABOMETYX® — against Cipla’s proposed generic formulation. These patents were registered with the U.S. Patent and Trademark Office (USPTO) and represent layered protection typical of a mature pharmaceutical compound patent portfolio.
- • US8877776B2 — Covering cabozantinib’s chemical composition and salt forms.
- • US11091440B2 — Covering cabozantinib’s chemical composition and salt forms.
- • US11298349B2 — Covering cabozantinib’s chemical composition and salt forms.
- • US11098015B2 — Covering cabozantinib’s chemical composition and salt forms.
- • US11091439B2 — Covering cabozantinib’s chemical composition and salt forms.
Developing a similar pharmaceutical compound?
Check if your drug formulation might infringe these or related patents before launch.
The Verdict & Legal Analysis
Outcome
Pursuant to Federal Rule of Civil Procedure 41, both parties jointly stipulated to dismiss all claims, counterclaims, defenses, motions, and petitions without prejudice. Each party agreed to bear its own costs and attorneys’ fees. No damages were awarded. The outcome reflects broader industry patterns in Hatch-Waxman litigation strategy.
Key Legal Issues
The action was initiated as a straightforward patent infringement action under the Hatch-Waxman Act framework, triggered by Cipla’s ANDA filing. Because the case was dismissed before any substantive rulings, there is no judicial determination regarding the validity of the asserted patents, whether Cipla’s proposed generic product would infringe, or claim construction of contested terms. This early dismissal most commonly reflects a confidential licensing or settlement agreement, or Cipla’s decision to withdraw or amend its ANDA.
Freedom to Operate (FTO) Analysis
This case highlights critical IP risks in pharmaceutical development. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this litigation.
- View all related patents in this therapeutic space
- See which companies are most active in oncology patents
- Understand claim construction patterns
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own drug compound or formulation.
- Input your drug compound or formulation details
- AI identifies potentially blocking patents
- Get actionable risk assessment report
Ongoing Risk Area
Generic cabozantinib entry remains uncertain
5 Asserted Patents
Covering cabozantinib composition
Strategic Dismissal
Preserves enforcement rights
✅ Key Takeaways
Rule 41 without-prejudice dismissals in Hatch-Waxman cases carry no preclusive effect — monitor for re-filing activity.
Search related case law →Five-patent assertions across continuation families maximize settlement leverage while managing claim construction risk.
Explore precedents →Frequently Asked Questions
Five U.S. patents were asserted: US8877776B2, US11091440B2, US11298349B2, US11098015B2, and US11091439B2 — covering cabozantinib (S)-malate compound and formulation claims.
Both parties jointly stipulated to dismissal under Fed. R. Civ. P. 41, with each bearing its own costs. No merits ruling was issued; the without-prejudice designation preserves Exelixis’s right to re-file.
The dismissal establishes no precedent on validity or infringement. Other generic manufacturers pursuing cabozantinib ANDAs face the same five-patent landscape with no judicial guidance on claim scope.
Ready to Strengthen Your Patent Strategy?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision.
References
- PACER (Case No. 1:24-cv-00565, D. Del.)
- USPTO Patent Center
- Cornell Legal Information Institute — Federal Rule of Civil Procedure 41
- PatSnap — IP Intelligence Solutions for Law Firms
This article is for informational purposes only and does not constitute legal advice. All case information is drawn from publicly available court records. For platform capabilities, visit PatSnap.